1. [1] Alles SR, Smith PA. Etiology and pharmacology of neuropathic pain. Pharmacol Rev 2018; 70: 315-347. [DOI:10.1124/pr.117.014399] [PMID]

2. [2] Abbadie C, Bhangoo S, De Koninck Y, Malcangio M, Melik-Parsadaniantz S, White FA, et al. Chemokines and pain mechanisms. Brain Res Rev 2009; 60: 125-134. [DOI:10.1016/j.brainresrev.2008.12.002] [PMID] [PMCID]

3. [3] Butt MS, Sultan MT. Coffee and its consumption: benefits and risks. Crit Rev Food Sci Nut 2011; 51: 363-373. [DOI:10.1080/10408390903586412] [PMID]

4. [4] de Mejia EG, Ramirez-Mares MV. Impact of caffeine and coffee on our health. Trends Endocrinol Metab 2014; 25: 489-492. [DOI:10.1016/j.tem.2014.07.003] [PMID]

5. [5] BONILHA L, LI LM. Heavy coffee drinking and epilepsy. Seizure 2004; 13: 284-285. [DOI:10.1016/S1059-1311(03)00079-7]

6. [6] Antonioli L, Csoka B, Fornai M, Colucci R, Kokai E, Blandizzi C, Haskó G. Adenosine and inflammation: what's new on the horizon? Drug Discov Today 2014; 19: 1051-1068. [DOI:10.1016/j.drudis.2014.02.010] [PMID]

7. [7] Guntz E, Dumont H, Pastijn E, d'Exaerde Ade K, Azdad K, Sosnowski M, et al. Expression of adenosine A 2A receptors in the rat lumbar spinal cord and implications in the modulation of N-methyl-d-aspartate receptor currents. Anesth Analg 2008; 106: 1882-1889. [DOI:10.1213/ane.0b013e318173251f] [PMID]

8. [8] Fredholm BB. Adenosine receptors as drug targets. Exp Cell Res 2010; 316: 1284-1288. [DOI:10.1016/j.yexcr.2010.02.004] [PMID] [PMCID]

9. [9] Chroscinska-Krawczyk M, Jargiello-Baszak M, Walek M, Tylus B, Czuczwar SJ, etal. Caffeine and the anticonvulsant potency of antiepileptic drugs: experimental and clinical data. Pharmacol Rep 2011; 63: 12-18. [DOI:10.1016/S1734-1140(11)70394-2]

10. [10] Sawynok J. Caffeine and pain. Pain 2011; 152: 726-729. [DOI:10.1016/j.pain.2010.10.011] [PMID]

11. [11] Wu WP, Hao JX, Fredholm BB, Wiesenfeld-Hallin Z, Xu XJ. Effect of acute and chronic administration of caffeine on pain-like behaviors in rats with partial sciatic nerve injury. Neurosci Lett 2006; 402: 164-166. [DOI:10.1016/j.neulet.2006.03.065] [PMID]

12. [12] Martins DF, Prado MR, Daruge‐Neto E, Batisti AP, Emer AA, Mazzardo‐Martins L, et al. Caffeine prevents antihyperalgesic effect of gabapentin in an animal model of CRPS‐I: evidence for the involvement of spinal adenosine A1 receptor. J Peripher Nerv Syst 2015; 20: 403-409. [DOI:10.1111/jns.12149] [PMID]

13. [13] Baratloo A, Rouhipour A, Forouzanfar MM, Safari S, Amiri M, Negida A. The Role of caffeine in pain management: a brief literature review. Anesth Pain Med 2016; 6: e33193. [DOI:10.5812/aapm.33193] [PMID] [PMCID]

14. [14] Tavares C, Sakata RK. Caffeine in the treatment of pain. Rev Bras Anestesiol 2012; 62: 387-401. [DOI:10.1016/S0034-7094(12)70139-3]

15. [15] Luongo L, Guida F, Imperatore R, Napolitano F, Gatta L, Cristino L, et al. The A1 adenosine receptor as a new player in microglia physiology. Glia 2014; 62: 122-132. [DOI:10.1002/glia.22592] [PMID]

16. [16] Tzabazis A, Kim PH, Sweitzer SM, Yeomans DC. Ameroid rings for gradual chronic constriction of the sciatic nerve in rats: contribution of different nerves to neuropathic pain. Brain Res Bull 2004; 64: 127-132. [DOI:10.1016/j.brainresbull.2004.05.006] [PMID]

17. [17] Pottabathini R, Kumar A, Bhatnagar A, Garg S. Possible involvement of nitric oxide modulatory mechanism in the protective effect of retigabine against spinal nerve ligation-induced neuropathic pain. Cell Mol Neurobiol 2015; 35: 137-146. [DOI:10.1007/s10571-014-0105-2] [PMID]

18. [18] Banafshe HR, Hajhashemi V, Minaiyan M, Mesdaghinia A, Abed A. Antinociceptive effects of maprotiline in a rat model of peripheral neuropathic pain: possible involvement of opioid system. Iran J Basic Med Sci 2015; 18: 752-757. [DOI:10.1016/S0924-977X(15)30280-7]

19. [19] Hamidi GA, Manaheji H, Janahmadi M, Noorbakhsh SM, Salami M. Co-administration of MK-801 and morphine attenuates neuropathic pain in rat. Physiol Behav 2006; 88: 628-635. [DOI:10.1016/j.physbeh.2006.05.017] [PMID]

20. [20] Martins DF, Prado MR, Daruge-Neto E, Batisti AP, Emer AA, Mazzardo-Martins L, et al. Caffeine prevents antihyperalgesic effect of gabapentin in an animal model of CRPS-I: evidence for the involvement of spinal adenosine A1 receptor. J Peripher Nerv Sys 2015; 20: 403-409. [DOI:10.1111/jns.12149] [PMID]

21. [21] Esser MJ, Chase T, Allen GV, Sawynok J. Chronic administration of amitriptyline and caffeine in a rat model of neuropathic pain: multiple interactions. Eur J Pharmacol 2001; 430: 211-218. [DOI:10.1016/S0014-2999(01)01276-6]

22. [22] Tomic MA, Vuckovic SM, Stepanovic-Petrovic RM, Ugresic N, Prostran MS, Boskovic B, etal. The anti-hyperalgesic effects of carbamazepine and oxcarbazepine are attenuated by treatment with adenosine receptor antagonists. Pain 2004; 111: 253-260. [DOI:10.1016/j.pain.2004.07.010] [PMID]

23. [23] Ongini E, Fredholm BB. Pharmacology of adenosine A2A receptors. Trends Pharmacol Sci 1996; 17: 364-372. [DOI:10.1016/S0165-6147(96)80010-1]

24. [24] Sawynok J. Adenosine receptor activation and nociception. Eur J Pharmacol 1998; 347: 1-11. [DOI:10.1016/S0014-2999(97)01605-1]

25. [25] Jacobson KA. Introduction to adenosine receptors as therapeutic targets. Handb Exp Pharmacol 2009; 193: 1-24. [DOI:10.1007/978-3-540-89615-9_1] [PMID] [PMCID]

26. [26] Fedele DE, Li T, Lan JQ, Fredholm BB, Boison D. Adenosine A1 receptors are crucial in keeping an epileptic focus localized. Exp Neurol 2006; 200: 184-190. [DOI:10.1016/j.expneurol.2006.02.133] [PMID]

27. [27] Gouder N, Fritschy JM, Boison D. Seizure suppression by adenosine A1 receptor activation in a mouse model of pharmacoresistant epilepsy. Epilepsia 2003; 44: 877-885. [DOI:10.1046/j.1528-1157.2003.03603.x] [PMID]

28. [28] Sawynok J, Reid AR, Doak GJ. Caffeine antinociception in the rat hot-plate and formalin tests and locomotor stimulation: involvement of noradrenergic mechanisms. Pain 1995; 61: 203-213. [DOI:10.1016/0304-3959(94)00169-F]

29. [29] Bruce C, Yates DH, Thomas PS. Caffeine decreases exhaled nitric oxide. Thorax 2002; 57: 361-363. [DOI:10.1136/thorax.57.4.361] [PMID] [PMCID]